cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

By rosaguerrero • May 2, 2022

Li S, Zeng W, Ni X, Zhou Y, Stackpole ML, Noor ZS, Yuan Z, Neal A, Memarzadeh S, Garon EB, Dubinett SM, Li W, Zhou XJ. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 May 2;28(9):1841-1853. doi: 10.1158/1078-0432.CCR-21-1242. PMID: 35149536; PMCID: PMC9126584.

Tags: Hematology/Oncology, Publications

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]

Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of two patients

Galamgam J, Baroni E, Tsai S, Cheng CE. Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of[...]

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani[...]